The intergroup rhabdomyosarcoma study-II

1993732 citationsJournal Article

Authors

Harold M. Maurer · Virginia Commonwealth University Medical Center

Edmund A. Gehan · Virginia Commonwealth University Medical Center

Mohan Beltangady · The University of Texas MD Anderson Cancer Center

William M. Crist · The University of Texas MD Anderson Cancer Center

Paul S. Dickman · Arcadia

Sarah S. Donaldson · The University of Texas MD Anderson Cancer Center

Christopher Fryer

Abstract

Combining all Groups and treatments in IRS-II, the major improvement in S rate at 5 years between studies was in nonmetastatic patients (71% for IRS-II versus 63% for IRS-I, P = 0.01).

Topics & Keywords

Sarcoma Diagnosis and Treatment Vascular Tumors and Angiosarcomas Surgical site infection prevention

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer

Volume 71, Issue 5, pp. 1904-1922

DOI: 10.1002/1097-0142(19930301)71:5<1904::aid-cncr2820710530>3.0.co;2-x

Field-Weighted Citation Impact: 18.98